Get started
Author

Yumiko Kobayashi

Observed name: Kobayashi Yumiko
ORCID: 0009-0009-0322-1494
Observed ORCID: 0009-0009-0322-1494
OpenAlex ID: A5041685860
Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024 · Shinji Nakamichi, Kaoru Kubota, et al. · Clinical Cancer Research · 15
PDF
Fever following Treatment with Atezolizumab plus Bevacizumab Predicts Liver Injury in Patients with Unresectable Hepatocellular Carcinoma: A Prospective Observational Analysis
2025 · Takanori Ito, Takafumi Yamamoto, et al. · Liver Cancer · 2
PDF
Exercise echocardiography in the evaluation of severity of functional mitral regurgitation in patients with heart failure
2010 · Yumiko Kobayashi, Yasushi Sakata, et al. · Journal of Echocardiography · 1
An RNA thermogenic therapy to preserve lean mass and enhance metabolic health during GLP-1 weight loss
2026 · Anneke K. Thorne, Nathan J. Waldeck, et al. · Proceedings of the National Academy of Sciences
Supplementary Table S2 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024 · Shinji Nakamichi, Kaoru Kubota, et al.
Supplementary Table S1 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024 · Shinji Nakamichi, Kaoru Kubota, et al.
Supplementary Figure S1 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024 · Shinji Nakamichi, Kaoru Kubota, et al.
Supplementary Table S6 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024 · Shinji Nakamichi, Kaoru Kubota, et al.
Supplementary Table S1 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024 · Shinji Nakamichi, Kaoru Kubota, et al.
Supplementary Table S4 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024 · Shinji Nakamichi, Kaoru Kubota, et al.
Supplementary Figure S3 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024 · Shinji Nakamichi, Kaoru Kubota, et al.
PDF
Supplementary Figure S2 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024 · Shinji Nakamichi, Kaoru Kubota, et al.
Supplementary Table S6 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024 · Shinji Nakamichi, Kaoru Kubota, et al.
Data from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024 · Shinji Nakamichi, Kaoru Kubota, et al.
Supplementary Table S5 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024 · Shinji Nakamichi, Kaoru Kubota, et al.
Data from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024 · Shinji Nakamichi, Kaoru Kubota, et al.
Supplementary Figure S3 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024 · Shinji Nakamichi, Kaoru Kubota, et al.
Supplementary Figure S1 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024 · Shinji Nakamichi, Kaoru Kubota, et al.
Supplementary Table S2 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024 · Shinji Nakamichi, Kaoru Kubota, et al.
Supplementary Table S3 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024 · Shinji Nakamichi, Kaoru Kubota, et al.
Supplementary Table S5 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024 · Shinji Nakamichi, Kaoru Kubota, et al.
Supplementary Figure S2 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024 · Shinji Nakamichi, Kaoru Kubota, et al.
PDF
Supplementary Table S4 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024 · Shinji Nakamichi, Kaoru Kubota, et al.
Supplementary Table S3 from Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)
2024 · Shinji Nakamichi, Kaoru Kubota, et al.
High-output heart failure caused by renal arteriovenous fistula
2009 · Kazuhiro Yamamoto, Yasushi Sakata, et al. · Journal of Medical Ultrasonics
Works count: 26
Citation count: 18
H-index: 2
I10-index: 1
Year
Topic
Type